April 20, 2017 Bio/Pharma/CRO Clinical Research/Diagn. Lab Top-10

Multi-Center Clinical Study Confirms Decreased Levels of Procalcitonin as an Independent Predictor of Mortality in Patients with Severe Sepsis and Septic Shock

Thermo Fisher Scientific Inc. today announced that results from the multi-center Procalcitonin MOnitoring SEpsis (MOSES) Study have been published in the May 2017 print issue of Critical Care Medicine. Researchers from the study, titled “Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study,” investigated the use of... Read more

April 19, 2017 Acad, Gov/Utilities Bio/Pharma/CRO PR/Corporate

Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS™ (ocrelizumab) in two types of multiple sclerosis

Basel, 19 April 2017 Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS™ (ocrelizumab) in two types of multiple sclerosis Data presentations will include platform sessions and posters across relapsing multiple sclerosis and primary progressive multiple sclerosis Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data on... Read more

April 18, 2017 Acad, Gov/Utilities Bio/Pharma/CRO

FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States

Basel, 18 April 2017 FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States First and only medicine approved to treat all forms of diabetic retinopathy Granted Priority Review Designation by the FDA based on analysis of results from a National Institutes of... Read more

April 18, 2017 Acad, Gov/Utilities Bio/Pharma/CRO

FDA grants Roche’s TECENTRIQ® (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer

Basel, 18 April 2017 FDA grants Roche’s TECENTRIQ® (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer First and only cancer immunotherapy approved in advanced bladder cancer as initial treatment for those unable to receive cisplatin chemotherapy Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug... Read more

April 18, 2017 Acad, Gov/Utilities Bio/Pharma/CRO

FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States

Basel, 18 April 2017 FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States First and only medicine approved to treat all forms of diabetic retinopathy Granted Priority Review Designation by the FDA based on analysis of results from a National Institutes of... Read more

April 17, 2017 Bio/Pharma/CRO Clinical Research/Diagn. Life Science Tools M&A, Partnerships PR/Corporate

Transgenomic Closes Bridge Financing

Proceeds Intended to Facilitate Completion of Merger with Precipio Diagnostics During Second Quarter of 2017 OMAHA, Neb. (April 17, 2017) — Transgenomic, Inc. (OTCQB: TBIO) today reported that it has received $1.15 million in proceeds from a note bridge financing.The financing is intended to help facilitate the completion of Transgenomic’s merger with Precipio Diagnostics, LLC,... Read more

April 17, 2017 Bio/Pharma/CRO

Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A

Basel, 17 April 2017 Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A Emicizumab prophylaxis reduced the number of bleeds in children with haemophilia A and inhibitors to factor VIII Results build upon data for emicizumab in adults and adolescents with haemophilia A and inhibitors to factor VIII... Read more

April 11, 2017 Bio/Pharma/CRO Informatics & Software Lab Top-10 Mass Spectrometry PR/Corporate Uncategorized

Companies collaborate at Danaher Life Sciences Biologics Day to present the latest technological developments for biopharmaceutical analysis

SCIEX features its ground-breaking biologics solutions including the X500B QTOF System and the Fast Glycan Labeling and Analysis Kit April 11, 2017 Framingham, MA — SCIEX, a Danaher company and global leader in life science analytical technologies, today announced that it presented the company’s latest ground-breaking biologics solutions at the Danaher Life Sciences Biologics Day.... Read more

April 11, 2017 Atomic Spectroscopy Bio/Pharma/CRO Lab Top-10

Effective Analysis of Elemental Impurities in Pharmaceuticals Using EDX Fluorescence Spectrometry Release of the Pharmaceuticals Impurities Screening Method Package

April 11, 2017 Shimadzu Corporation has released the pharmaceuticals impurities screening method package as a solution for use with its EDX-7000 energy dispersive X-ray fluorescence spectrometer. This package is suitable for the analysis of elemental impurities in pharmaceuticals. This package contains conditions for two methods. This enables the efficient analysis of a total of 12... Read more

April 11, 2017 Bio/Pharma/CRO Molecular Spectroscopy

Effective Analysis of Elemental Impurities in Pharmaceuticals Using EDX Fluorescence Spectrometry Release of the Pharmaceuticals Impurities Analysis Method Package

Analysis with the EDX-7000 can be started by putting the sample in the special container and placing it in the instrument. There is no need to chemically pretreat the sample. Special gases and vacuum conditions are unnecessary, and since it operates on household power supply, installation is easy. In addition, by incorporating two kinds of... Read more